NASDAQ:PDLI - PDL BioPharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.39 +0.01 (+0.30 %)
(As of 04/26/2019 12:01 PM ET)
Previous Close$3.38
Today's Range$3.36 - $3.41
52-Week Range$2.25 - $3.89
Volume11,891 shs
Average Volume1.55 million shs
Market Capitalization$434.29 million
P/E Ratio9.18
Dividend YieldN/A
Beta0.59
PDL BioPharma, Inc. acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in the United States, Europe, and internationally. The company operates in three segments: Pharmaceutical, Medical Devices, and Income Generating Assets. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Medical Devices segment manufactures, markets, and sells LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Receive PDLI News and Ratings via Email

Sign-up to receive the latest news and ratings for PDLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:PDLI
CUSIP69329Y10
Phone775-832-8500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$198.11 million
Cash Flow$0.5313 per share
Book Value$5.00 per share

Profitability

Net Income$-68,860,000.00

Miscellaneous

Employees105
Market Cap$434.29 million
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable

PDL BioPharma (NASDAQ:PDLI) Frequently Asked Questions

What is PDL BioPharma's stock symbol?

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

How will PDL BioPharma's stock buyback program work?

PDL BioPharma announced that its board has approved a stock buyback plan on Monday, September 24th 2018, which permits the company to buyback $100,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to buy up to 27.3% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's leadership believes its stock is undervalued.

How were PDL BioPharma's earnings last quarter?

PDL BioPharma Inc (NASDAQ:PDLI) released its quarterly earnings results on Thursday, March, 14th. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.02. The biotechnology company earned $45.12 million during the quarter. PDL BioPharma had a positive return on equity of 6.76% and a negative net margin of 34.76%. During the same period in the prior year, the firm earned $0.15 EPS. View PDL BioPharma's Earnings History.

When is PDL BioPharma's next earnings date?

PDL BioPharma is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for PDL BioPharma.

What price target have analysts set for PDLI?

1 brokerages have issued 12 month target prices for PDL BioPharma's stock. Their forecasts range from $3.00 to $3.00. On average, they expect PDL BioPharma's share price to reach $3.00 in the next twelve months. This suggests that the stock has a possible downside of 11.5%. View Analyst Price Targets for PDL BioPharma.

What is the consensus analysts' recommendation for PDL BioPharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDL BioPharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PDL BioPharma.

Has PDL BioPharma been receiving favorable news coverage?

News headlines about PDLI stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PDL BioPharma earned a news impact score of 2.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the near future.

Who are some of PDL BioPharma's key competitors?

What other stocks do shareholders of PDL BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PDL BioPharma investors own include AT&T (T), Advanced Micro Devices (AMD), Novavax (NVAX), Opko Health (OPK), Canopy Growth (CGC), General Electric (GE), Teva Pharmaceutical Industries (TEVA), Bank of America (BAC), Prospect Capital (PSEC) and Synergy Pharmaceuticals (SGYP).

Who are PDL BioPharma's key executives?

PDL BioPharma's management team includes the folowing people:
  • Mr. Dominique P. Monnet, CEO, Pres & Director (Age 58)
  • Mr. Peter S. Garcia, VP & CFO (Age 57)
  • Mr. Christopher L. Stone, VP, Gen. Counsel & Sec. (Age 55)
  • Mr. Nathan Kryszak, Deputy Gen. Counsel & Assistant Sec.

Who are PDL BioPharma's major shareholders?

PDL BioPharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Strs Ohio (0.15%), Virginia Retirement Systems ET AL (0.09%), Mercer Global Advisors Inc. ADV (0.05%) and Meeder Asset Management Inc. (0.02%). View Institutional Ownership Trends for PDL BioPharma.

Which major investors are selling PDL BioPharma stock?

PDLI stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio and Meeder Asset Management Inc.. View Insider Buying and Selling for PDL BioPharma.

Which major investors are buying PDL BioPharma stock?

PDLI stock was bought by a variety of institutional investors in the last quarter, including Virginia Retirement Systems ET AL and Mercer Global Advisors Inc. ADV. View Insider Buying and Selling for PDL BioPharma.

How do I buy shares of PDL BioPharma?

Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PDL BioPharma's stock price today?

One share of PDLI stock can currently be purchased for approximately $3.39.

How big of a company is PDL BioPharma?

PDL BioPharma has a market capitalization of $434.29 million and generates $198.11 million in revenue each year. The biotechnology company earns $-68,860,000.00 in net income (profit) each year or $0.37 on an earnings per share basis. PDL BioPharma employs 105 workers across the globe.

What is PDL BioPharma's official website?

The official website for PDL BioPharma is http://www.pdl.com.

How can I contact PDL BioPharma?

PDL BioPharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected]


MarketBeat Community Rating for PDL BioPharma (NASDAQ PDLI)

Community Ranking:  1.4 out of 5 (star)
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  399 (Vote Underperform)
Total Votes:  555
MarketBeat's community ratings are surveys of what our community members think about PDL BioPharma and other stocks. Vote "Outperform" if you believe PDLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel